According to healthcare research reports on colorectal cancer it is one of the most fatal forms of cancer that accounts for the maximum number of cancer related deaths in the world. Even with sufficient advances in the molecular understanding of the disease, the colorectal cancer drug market is constantly vying to develop complex compounds with specific molecular targets that are required to treat the disease by addressing the complex pathways of the cancerous cells. However, most of these selective drugs are presently in preclinical and early clinical stages.

With an improved understanding of colorectal cancer, its widespread growth and spread has enabled the colon cancer market to develop strategies that lead to improved cures for patients. Furthermore, better understanding of the genetic alterations that contribute to the occurrence of colorectal cancer development and spread, have further led to the manufacturing of drugs that obstruct the growth of the tumor.

Currently, more than 300 companies are manufacturing more than 400 different drugs that target colorectal cancer. Moreover, according to colon cancer research, there are another 200 drugs that have been either ceased or suspended. Only until a decade ago, did Leucovorin form the mainstream drug to treat the cancer while Eloxatin established itself as the main component of therapy. The advent of the molecular targeted agents like the Avastin and Erbitux welcomed a new era in disease management wherein the survival levels improved greatly.

With the new molecularly targeted drugs, colon cancer research suggests that the survival rate has increased significantly. The drugs like bevacizumab are able to target the inherent abnormal pathways in the cancer cells and are much less toxic than the traditional selective chemotherapeutics. Furthermore, with the US Food and Drug approving the molecular drugs for the treatment of mCRC in the clinic, the survival rates have greatly improved and progression rate of the cancerous cells have progressively decreased. This means that a host of new opportunities have opened up for the treatment of this particular cancerous condition and other related malignancies, which in turn has further spurred the development of the selective targeting drug development market.


[b]For further insights, [/b]

Visit: http://www.researchonglobalmarkets.com/colon-cancer-pipeline-review-h1-2014.html


[b]About Research on Global Markets[/b]

Research on Global Markets is a leading source for market research on various sectors globally, offering premium research content from worldwide publishers of market research reports. Our database hosts premium market research content developed by global publishers. It offers premium industry research reports, company profiles and country briefs. We have a dedicated team of research professionals who can facilitate, in an unbiased manner, the process of identifying appropriate market research reports that are targeted to fulfill all your information-related requirements.


[b]For more details on the content of each report and ordering information please contact:[/b]

Email: [email protected]
US: +1 800 986 6819
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.com
Blog: blog.researchonglobalmarkets.com